EGFR and cancer: Novel chemotherapeutic agents, like S-1, immune checkpoint inhibitors in cancer immunotherapy, fibroblastic or epidermal growth factor receptor inhibitors, and an ever-expanding array of monoclonal antibodies that target neoplastic conditions (e.g., bentamab mafodotin for multiple myeloma), are only some of the newest developed anticancer drugs.